关于停药的相关内容

摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。
' z0 Y. a! Z% o: _    关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。
+ X5 d$ A" l, v: a! ~9 o7 d
% n( `* G+ P1 d% @作者：来自澳大利亚
来源：Haematologica. 2011.8.9.
4 f1 G+ M! T( b$ pDear Group,
* y2 }/ l9 o& q6 S/ ]
: r! t2 F. c# L6 m3 ~Some of you are on Dasatinib (Sprycel) and we wish to give news on all CML
therapies. Here is a report from Australia on 3 patients who went off Sprycel
- |" O  U, F6 W" c+ _4 O; [+ j% Hafter stable molecular response (PCRU). 1 patient relapsed but 2/3 patients
remain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel
7 [. R5 J- Y( p4 U. Q6 Edoes spike up the immune system so I hope more reports come out on this issue.

  J9 N% o8 C8 A7 mThe remarkable news about Sprycel cessation is that all 3 patients had failed
3 l- G! Q6 u0 ~- L+ s7 fGleevec and Sprycel was their second TKI so they had resistant disease. This is
1 x; f; F2 d  I: n8 A* P5 Xdifferent from the stopping Gleevec trial in France which only targets patients
who have done well on Gleevec.
" |& P' F# i9 t5 R9 f! @8 M$ j2 A; o; M
% L- K* \6 B/ L5 R+ u! b# x# DHopefully, the doctors will report on a larger study and long-term to see if the
2 [: m" [  R2 z1 L" M' b, Presponse off Sprycel is sustained.
5 {1 C- C1 L) A0 H, N6 @. ~( z% t
; q2 h  h1 ^/ V, EBest Wishes,
: F7 H4 E) t  C3 V0 W1 C$ G/ r; wAnjana


0 ^) E6 m* y4 S7 h4 b/ [" ]' F
Haematologica. 2011 Aug 9. [Epub ahead of print]
; ~" k5 W. N) b1 v6 ]5 d; LDurable complete molecular remission of chronic myeloid leukemia following
( R- j* L# Z5 [dasatinib cessation, despite adverse disease features.
8 F3 J, p: r1 }7 p% H6 bRoss DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.
Source
Adelaide, Australia;
  K7 |' I1 n* M
Abstract
. m' h1 I3 }+ R& p! TPatients with chronic myeloid leukemia, treated with imatinib, who have a
/ H8 x3 S( k+ z  m9 Rdurable complete molecular response might remain in CMR after stopping
treatment. Previous reports of patients stopping treatment in complete molecular
response have included only patients with a good response to imatinib. We
: Q$ k  A$ P# ]. A  r0 `0 jdescribe three patients with stable complete molecular response on dasatinib
treatment following imatinib failure. Two of the three patients remain in
+ v$ v2 |6 P, q% I" ncomplete molecular response more than 12 months after stopping dasatinib. In
these two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to
show that the leukemic clone remains detectable, as we have previously shown in
imatinib-treated patients. Dasatinib-associated immunological phenomena, such as
9 K' T! k3 _7 n6 M6 {. N* ~4 ]8 _$ dthe emergence of clonal T cell populations, were observed both in one patient
who relapsed and in one patient in remission. Our results suggest that the
2 L7 |8 e% }& y" S+ L* U1 E1 ~characteristics of complete molecular response on dasatinib treatment may be
similar to that achieved with imatinib, at least in patients with adverse
4 {: _# T+ i% x9 E9 k% @6 Odisease features.
. m) d$ i6 ]+ M# z0 h4 \6 z

摘要：（STIM试验为法国的格列卫停药试验。）这个研究中，患者先是取得了CMR（融合基因转阴），然后停用格列卫，而后复发。15名复发患者在重新服药后又一次取得了CMR，他们同意再次停药。
    第一次CMR持续时间为31个月，然后患者停药，复发的中位时间为2.6个月，然后重新服用格列卫，中位时间5.3个月之后取得第二次CMR。保持第二次CMR中位时间19个月之后，患者同意再次停药，这次，15名患者中有5名在停药随访中位时间24个月后仍然保持了CMR，而10名患者在停药中位时间2月后第二次复发。
' w! J( O. q" l7 h    请注意，这些患者都是在第一次CMR后停药然后又复发的患者。
1 W9 }' j5 K  y+ t
7 |6 W0 q/ h8 u% r1 A0 x8 ~作者：来自法国STIM试验
来源：EHA 2011.6.会议摘要

很不错的文章，看来马老师家有考虑停药的想法了啊！祝福！

期盼易或特也能停药，但现在觉得是一个梦想！

这个非常有意义的研究。能吃下来停会再吃，再停，那是天大的好事